Clinical Trial Update: Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 trial compares SAF-189s to Crizotinib as first-line therapy for ALK-positive advanced/metastatic non-small cell lung cancer; the study is currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)
• SAF-189s (SAF-189s)

Snippet

Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Conditions: Non-Small Cell Lung Cancer, ALK-positive | Phase 3 | Status: ACTIVE_NOT_RECRUITING